LXEO

Equibles Rating blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −26%

below

Price vs 50-day avg +4%

above

RSI (14) 60

neutral

MACD trend Positive

52-week position 23%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +25%

trailing

6-month return −29%

trailing

YTD return −47%

this year

Relative strength −36%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $5 › 200d $7 — 200d above 50d

Institutional flow Accumulating

2 of 139 funds reported for Jun 30 · net +265.6K sh shares · +1 new

Insider flow Distributing

Net -$280.1K over 90 days · 100% sells

Short interest Rising

17.94% of float · ▲ +2.3% MoM · 18.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

139 holders — mid 2-yr range

Squeeze score 77

high risk · 0–100

Fundamentals

Strong

EPS growth +40%

Y/Y

Free cash flow $-99.0M

Balance sheet $63.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 79%

annualized · 1-yr

Max drawdown −61%

past year

ATR 6.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Jul 29, 2026 Est · unconfirmed · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 11, 2026

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−26% Bearish

Price vs 50-day avg

+4% Bullish

RSI (14)

60 Neutral

MACD trend

Positive Bullish

52-week position

23% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $5 › 200d $7 — 200d above 50d

Institutional flow Accumulating

2 of 139 funds reported for Jun 30 · net +265.6K sh shares · +1 new

Insider flow Distributing

Net -$280.1K over 90 days · 100% sells

Short interest Rising

17.94% of float · ▲ +2.3% MoM · 18.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

139 holders — mid 2-yr range

Price context

position in its 52-week range

52-wk low $4 Now $5 · 23% 52-wk high $11

vs 200-day avg -26% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Cash, cash equivalents, and investments in marketable securities	$227.6M	Q1 2026	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
LXEO Lexeo Therapeutics, Inc. this stock	$414.59M	-46.8%	—	—	17.9%
ONC BeOne Medicines Ltd.	$446.53B	+1.7%	+22179.2%	908.7	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$126.50B	+9.9%	+46.2%	29.6	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.50B	-14.0%	+20.8%	16.2	3.2%
ARGX Argenx SE	$57.20B	+8.8%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

140

% held: 101.4%
Reported: 2 of 139
Top holder: Paradigm Biocapital Advis…

Held Float

View

Held by Funds

Fund positions

134

View

Short & Settlement

Short Interest Rising

Shares short

14.1M

Days to cover: 18.8d
Change: +313.0K sh

View

Short Volume

Short vol %

84%

As of: Jul 8, 2026

Short Total

View

Fails to Deliver

FTD shares

1.8K

Value: $7.7K
As of: Jun 9, 2026

View

Off-Exchange

Off-exchange %

34.0%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$280.1K

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Financials

Revenue (FY)

$654.0K

Net income (FY): $-100.0M
EPS diluted: $-1.86

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 29, 2026
This year: 11

View

Proposed Sales

Value

$116.2K

Shares: 25.9K
Filed: Jul 1, 2026

View

Earnings & Events

Earnings Calls

Last call

May 11, 2026

View

Performance

	5D	20D	120D	MTD	YTD
LXEO	+13.4%	+25.4%	-28.9%	+13.4%	-46.8%
SPY	-0.2%	+0.8%	+7.4%	-0.2%	+9.3%
vs SPY	+13.6%	+24.6%	-36.4%	+13.6%	-56.1%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance